Pharmaprojects R&D Pipeline News Feed
Brilinta meets Phase III primary endpoint
18 May 2009
AstraZeneca's oral P2Y12 ADP purinoreceptor antagonist Brilinta (ticagrelor) has met its primary endpoint in the Phase III 'PLATO' trial. The global safety and efficacy study, in 18624 patients with acute coronary syndrome, was designed to compare ticagrelor to Sanofi-Aventis and Bristol-Myers Squibb's successful antithrombotic clopidogrel (Plavix), first launched for the treatment of atherothombotic disease in 1998.
In the trial, Brilinta was examined on its ability to reduce time to myocardial infarction, stroke or cardiovascular death, and additionally demonstrated a safety profile in line with that observed in Phase II studies. Further analysis is ongoing.
Brilinta is structurally distinct from thienopyridines such as Plavix and the newer Efient (prasrugel) and AstraZeneca plans to submit registration filings for Brilinta in the fourth quarter of 2009.
